Jairam, R. Lingappa; Jared, M. Baeten; Anna, Wald; James, P. Hughes; Katherine, K. Thomas; Andrew, Mujugira; Nelly, Mugo; Elizabeth, A. Bukusi; Craig R., Cohen; Elly, Katabira; Allan, Ronald; James, Kiarie; Carey, Farquhar; Grace, John Stewart; Joseph, Makhema; Myron, Essex; Edwin, Were; Kenneth, H. Fife; Guy de, Bruyn; Glenda, E. Gray; James, McIntyre; Rachel, Manongi; Saidi, Kapiga; David, Coetzee; Susan, Allen; Mubiana, Inambao; Kayitesi, Kayitenkore; Etienne, Karita; William, Kanweka; Sinead, Delany; Helen, Rees; Bellington, Vwalika; Amalia, Magaret; Richard S., Wang; Lara, Kidoguchi; Linda, Barnes; Renee, Ridzon; Lawrence, Corey; Connie, Celum
(NIH Lancet public access, 2010-05-05)
Background—Well-tolerated medications that slow HIV-1 disease progression and delay initiation
of antiretroviral therapy (ART) are needed. Most HIV-1-infected persons are dually-infected with
herpes simplex virus type 2 ...